INVARIANT LLC for CIGNA CORPORATION
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
P.L. 117-103, the Consolidated Appropriations Act, 2022. Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. HR. 6833/S. 3700, the Affordable Insulin Now Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BENJAMIN KLEIN | — |
| KATHRYN WISE | — |
Medicare/Medicaid MMM
Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. S. 3593, Telehealth Extension and Evaluation Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BENJAMIN KLEIN | — |
| KATHRYN WISE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.